Company Page
mbiomics
Founders
mbiomics is a pioneering techbio company advancing scalable microbiome-based therapeutics for severe and chronic diseases. The company develops Live Biotherapeutic Products (LBPs) composed of live bacterial strains designed to restore the functional and metabolic potential of the gut microbiome. mbiomics leverages a proprietary platform combining AI/ML-driven consortia design, precision analytical technology, and large consortium co-cultivation to rationally design defined, large, and complex microbial consortia. The company is initially focusing on immuno-oncology, with lead candidate MBX-116 being developed as an immune checkpoint inhibitor co-therapy in advanced melanoma, while also building a broader pipeline for autoimmune and neurodegenerative diseases.
Company Founded in 2020
Healthtech & Biotech